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Abstract
Background: Research indicates that the etiology of autism has a strong genetic component, yet
so far the search for genes that contribute to the disorder, including several whole genome scans,
has led to few consistent findings. However, three studies indicate that the complement C4B gene
null allele (i.e. the missing or nonfunctional C4B gene) is significantly more frequent in individuals
with autism. Due to the close proximity of the CYP21A2 gene to the C4B locus (3 kb) it was decided
to examine samples from autistic subjects, including many with known C4B null alleles for common
CYP21A2 mutations.
Methods:  Samples from subjects diagnosed with autism and non-autistic controls (controls)
previously typed for C4B null alleles were studied. Allele specific polymerase chain reaction (PCR)
methods were used to determine 8 of the most common CYP21A2 genetic mutations, known to
completely or partially inhibit 21-hydroxylase, the enzyme encoded by the CYP21A2 gene.
Results: Although the combined autism and control study subjects had 50 C4B null alleles only 15
CYP21A2 mutations were detected in over 2250 genotypes. Eight mutations were detected in the
autistic samples and 7 in the controls. The frequency of CYP21A2 mutations was similar between
the autism and control samples. Only one individual (autistic) carried a chromosome containing
both C4B null allele and CYP21A2 mutations.
Background
Autism is a severe neurodevelopmental disorder that is
approximately four times more common in males than
females. The current prevalence for the disorder is approx-
imately 1 in 152 children [1]. Although there are various
mechanisms that can lead to this behaviorally defined
condition, in most cases the etiology remains unknown. A
strong genetic component clearly exists [2]; however, con-
sistent detection of disease associated genetic variants has
rarely been reported. Whole genome scans using microar-
ray technology may better detect the genetic contributions
to autism susceptibility [3].
Genes located in the RCCX module found on chromo-
some 6 in the human leukocyte antigen (HLA) locus are
associated with various disease states [4,5]. This module
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contains the genes RP, C4, CYP21, and TNX (abbreviated
RCCX) in a contiguous sequence. Different variants of
these four genes can exist in the RCCX module including
RP1 or RP2, C4A or C4B (long or short), CYP21A2 or
CYP21A1P, and TNXA or TNXB. RP2 and TNXA are gene
fragments while CYP21A1P  is a pseudogene. A single
chromosome usually contains one, two, three RCCX mod-
ules in tandem, but rare cases can have four modules.
Because of the diversity in the number and size of the
RCCX modules misalignments and unequal crossovers
occur during meiosis resulting frequently in deletions,
conversions, duplications along with the acquisition of
mutations from nearby pseudogenes or gene segments
[6]. One such mutation in this module is the missing/
nonfunctional C4A or C4B gene (C4 null allele). There-
fore, the C4  containing complex is an extraordinarily
complex region of the human genome [7] (Figure 1).
The RCCX module may play a significant role in the
genetic underpinnings of autism. Several studies have
shown that the frequency of C4B null alleles is increased
in individuals with autism [8-10], the most recent of
which found that 42.4% of autistic subjects carry a C4B
null allele compared to 14.5% of controls [10]. The
CYP21A2 gene is located approximately 3 kb downstream
of C4 and the concurrent deletion of C4B with portions of
the CYP21A2 has been described [11,12]. Therefore, the
aim of the present research was to determine if the C4B
null allele, found frequently in subjects with autism, is
associated with CYP21A2 mutations. As well, the overall
frequency of CYP21A2 mutations in autistic verses control
subjects was determined.
C4  genes encode innate immune C4 proteins that are
important in the complement cascade. CYP21A2 encodes
an enzyme, 21-hydroxylase, which is important in the
synthesis of cortisol and in maintaining proper androgen
levels.
Over 2,250 genetic typings of CYP21A2 mutations were
completed in 80 autistic and 60 controls subjects that had
previously been typed for C4B null alleles [10]. Fifteen
total CYP21A2 mutations where detected; however, only
one individual (autistic) carried a chromosome contain-
ing both a C4B null allele and CYP21A2 mutations. There-
fore, in these subjects it does not appear that C4B null
alleles are associated with the CYP21A2 mutations stud-
ied.
Methods
Subjects
This study utilized samples previously characterize for
C4A and C4B null alleles in an autism case-control study
[10]. Autistic subjects and controls were Caucasian of
Northern European descent and IRB (Utah State Univer-
sity) approval was obtained for this study. As reported, the
subjects were diagnosed with autism using DSM-IV crite-
ria by pediatric psychiatrists and psychologists expert in
the evaluation of autism. The Autism Diagnostic Observa-
tion Schedule (ADOS) [13] and the Autism Diagnostic
Inventory (ADI) [14] confirmed the Diagnosis. Various
CYP21A2 genetic determinations were completed in 80
individuals with autism (8 female, 72 male) and 60 con-
trol subjects (15 female, 45 male). Parents of the particu-
lar subjects were typed if their child was positive for a
mutation.
DNA preparation
DNA samples were extracted from peripheral blood
mononuclear cells as previously described [15]. To geno-
type samples with limited amounts of DNA, whole
genome amplification was performed using multiple dis-
placement amplification (MDA) based on the method of
Dean et al.[16]. MDA was performed using RepliPHI™ Phi
Three common arrangements of the RCCX module Figure 1
Three common arrangements of the RCCX module. 
Monomodular, bimodular, and trimodular are present in 
about 17, 69 and 14% of chromosomes, respectively [7]. The 
C4 gene which is either C4A or C4B can be either a long or 
short variant depending upon the presence of a 6.36 kb 
endogenous retrovirus, HERV-K(C4). Pseudogenes or gene 
fragments are red. CYP21A1* indicates either a CYP21A1P 
pseudogene or the CYP21A2 gene. In the present study 40 
chromosomes from autistic individuals had a C4B null allele. 
Of these chromosomes 19 were monomodular and 21 were 
bimodular. In the control subjects with C4B null alleles 10 
chromosomes were monomodular and 1 was bimodular. 
Bimodular C4B null alleles were significantly more frequent in 
autistic subjects compared to controls (P = 0.0001). No C4B 
null alleles or CYP21A2 mutations were detected in the sub-
jects (2 autistic, 4 control) with trimodular RCCX modules, 
determined by protein immunofixation electrophoresis [10].
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29 Reagent Sets (Epicentre®Technologies, Madison, Wis-
consin).
PicoGreen®  quantitation of amplified DNA was per-
formed using a Quant-iT™ DNA Assay Kit from Molecular
Probes™ (Eugene, Oregon) according to kit protocol. Flu-
orescence was measured with a Synergy HT microplate
reader (BIO-TEK®, Winooski, Vermont).
Polymerase chain reaction
Seven mutations were determined by allele-specific
polymerase chain reaction (PCR) based on the method of
Wilson et al.[17]. This method is as accurate as the dot
blot procedure [17]; therefore, it is sensitive enough to
detect a mutation in only one CYP21A2 gene if more than
two copies of the gene are present. The mutations ana-
lyzed included amino acid substitutions (P30L, I172N,
V281L, R356W, exon 6 cluster mutation (L236N, V237Q,
M239K)), a splicing mutation (intron 2 (656) A/C to G),
and a deletion (exon 3, 8 base pair deletion). Each reac-
tion contained a primer specific for either the common or
rare genetic variant in conjunction with a primer that
amplified only the CYP21A2 gene and not the pseudog-
ene (Table 1). A PCR based assay for detection of a 30 kb
deletion/conversion affecting both C4B and CYP21A2 was
performed based upon the method described in Keen-
Kim et al.[18].
Statistics
Chi-square analysis along with the Fisher's Exact Test
where performed using SPSS 14 (SPSS Inc., Chicago, Illi-
nois). A two-tailed test with a P-value of < 0.05 was con-
sidered significant after Bonferoni corrections for multiple
comparisons.
Results and discussion
Although the 80 autistic individuals studied had 40 C4B
null alleles and the 60 control individuals had 10 C4B
null alleles only 15 total CYP21A2  mutations were
detected in over 2250 genotypes. Eight CYP21A2 muta-
tions were detected in the autistic subjects and 7 in the
controls (Table 2). Only one individual (autistic) had a
chromosome carrying both a C4B  null allele and a
CYP21A2 mutation. Therefore, no association was deter-
mined between C4B null alleles and CYP21A2 mutations
in the study subjects.
Overall, the number of CYP21A2 mutations did not differ
between the autism and control groups and no group dif-
ferences were found in frequencies of individual CYP21A2
mutations. The frequency of CYP21A2 mutations seen in
this research is similar to general population frequencies
reported by others [19]. Five individuals with autism
(6.25%) and five controls (8.33%) carried a CYP21A2
mutation. Two individuals with autism and one control
Table 1: Sequences of oligonucleotide primers for allele-specific PCR
CYP21A2 Mutations [ref] rs # Primer 5'-Sequence-3'
30 kb deletion [18] common forward gcttcttgatgggtgatcaat
rare forward tccccaatccttactttttgtc
reverse cctcaatcctctgcagcg
V281L [17] rs6471 common reverse tccactgcagccatgtgcac
rare reverse tccactgcagccatgtgcaa
forward gagggatcacatcgtcgtggagatg
I172N [17] rs34607927 common forward tcctcacctgcagcatcat
rare forward ctctcctcacctgcagcatcaa
reverse agctgcatctccacgatgtga
R356W [17] common reverse ctaagggcacaacgggccg
rare reverse ctaagggcacaacgggcca
forward gagggatcacatcgtcgtggagatg
P30L [17] common forward tccggagcctccacctccc
rare forward tccggagcctccacctcct
reverse agctgcatctccacgatgtga
IN2 (656) A/C to G [17] common forward (A) ttcccaccctccagcccccaa
common forward (C) ttcccaccctccagcccccac
rare forward ttcccaccctccagcccccag
reverse agctgcatctccacgatgtga
Ex 3 (8 bp deletion) [17] common forward cggacctgtccttgggagactac
rare forward actacccggacctgtccttggtc
reverse agctgcatctccacgatgtga
Ex 6 cluster (see reference 17 for further description)
L236N common reverse agctgcatctccacgatgtga
V237Q rs12530380 rare reverse tcagctgcttctcctcgttgtgg
M239K rs6476 forward cggacctgtccttgggagactacBMC Medical Genetics 2008, 9:1 http://www.biomedcentral.com/1471-2350/9/1
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subject carried two or three mutations. In these cases the
mutations all typed to individual parents. Thus, the mul-
tiple mutations were found on single chromosomes.
When a mutation was found in the child's DNA it was also
present in DNA from one of the parents, thus confirming
both accurate typing and absence of de novo mutations in
the study children.
HLA extended haplotyes known to contain C4B null alle-
les are increased in frequency in autistic individuals (i.e.
HLA extended haplotypes 35.2 (n = 4), 35.3 (n = 2), 44.1
(n = 8), and 58.1 (n = 1)). Extended haplotypes 35.3 and
58.1 have monomodular RCCX structures (C4A: C4B null
allele) and extended haplotypes 35.2 and 44.1 are bimod-
ular (C4A, C4A:C4B null allele). No CYP21A2 mutations
were observed in these haplotypes.
The HLA 8.1 is present in 10% of the Caucasian popula-
tion and represents the most common extended haplo-
type. It has a monomodular RCCX structure with a C4A
null allele and a normal C4B gene (C4A null allele: C4B).
This extended haplotype, referred to as COX in the MHC
Haplotype Project [20], has been completely sequenced
[21]. Of the eighteen subjects with an 8.1 extended haplo-
type one had the rare SNP creating the TTG codon that
encodes for leucine at position 281 while 17 subjects had
the common codon GTG that encodes for valine at posi-
tion 281. This observation is in agreement with DNA
sequencing data that shows low level SNP diversity in 8.1
extended haplotypes from different individuals [22].
The specific CYP21A2  mutations were chosen because
they are the most common mutations that result in signif-
icant decreases in 21-hydroxylase activity. One of the
mutations investigated was a 30 kb deletion/conversion
that deletes C4B and converts CYP21A2 into a nonfunc-
tional CYP21A1P/CYP21A2  hybrid with its pseudogene
(Figure 2). This mutation was of particular interest
because it provides a direct link between a C4B null allele
and a CYP21A2 mutation. One autistic subject and two
controls carried this mutation. Again, these three poly-
morphisms were inherited and did not involve de novo
mutations.
It has been reported that two of the mutations, P30L and
V281L, partially inhibit 21-hydroxylase activity (30–60%
of normal), whereas the other mutations analyzed cause
either complete or nearly complete enzyme inhibition
[23]. Four subjects with autism (5%) carried a partially
inhibiting mutation (P30L or V281L) compared to two
control subjects (3.33%). This difference is not statisti-
cally significant.
21-hydroxylase deficiency is the most common cause of
congenital adrenal hyperplasia. Some evidence supports
the idea of 21-hydroxylase being involved in autism [24],
which could result in the excessive androgen production
seen in some cases [25] and thereby contribute to disease
etiology [26,27]. The present data does not provide
genetic support for 21-hydroxylase involvement in
autism.
Conclusion
This study examined both mono and bimodular RCCX
genetic modules that contain C4B null alleles for muta-
tions in the adjoining CYP21A2 gene. The C4B null alleles
seen in autism are not associated with the CYP21A2
genetic mutations examined in this study. The frequency
of CYP21A2 mutations was similar between the autism
and control groups. Based on family typings no de novo
mutations of C4B or CYP21A2  were apparent in study
subjects. Therefore, the CYP21A2 mutations studied do
not appear to contribute to the etiology of autism. How-
ever, a role for CYP21A2 in autism cannot be ruled out as
The 30 kb deletion/conversion of C4B and CYP21A2 Figure 2
The 30 kb deletion/conversion of C4B and CYP21A2. 
This diagram depicts the most common arrangement of the 
RP, C4, CYP21, and TNX (RCCX) gene module. Pseudogenes 
or gene fragments are red. The 30 kb deletion removes part 
of CYP21A1P, TNXA, RP2, C4B and part of CYP21A2 leaving a 
non-protein encoding CYP21A1P/CYP21A2 region.
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Table 2: Frequencies of the C4B null allele and CYP21A2 
mutations
Autism Control P-value
C4B null allele 40/160 10/120 P = 0.0003
30 kb deletion/conversion 1/160 2/120 Not significant (NS)
CYP21A2 mutations
V281L 3/160 1/120 NS
I172N 1/160 2/120 NS
R356W 1/160 0/120 NS
P30L 2/160 1/120 NS
IN2 0/160 0/120 NS
Ex 3 Del 0/160 1/120 NS
Ex 6 cluster 0/160 0/120 NSBMC Medical Genetics 2008, 9:1 http://www.biomedcentral.com/1471-2350/9/1
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other factors affecting CYP21A2 gene expression such as
promoter polymorphisms or epigenetic variation were
not studied and may be relevant [28]. As well, a weak
association may be beyond the statistical power of the
present study to detect.
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